A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma
OBJECTIVES: I. Determine the safety and efficacy of temozolomide in patients with recurrent
malignant glioma. II. Determine the radiographic response to this regimen in these patients.
III. Determine the time to tumor progression of these patients on this regimen. IV.
Determine the quality of life of these patients.
OUTLINE: Patients receive oral temozolomide once daily for 42 days. Courses repeat every 70
days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed every 1-2 months. Patients are followed every 3-4 months.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Lauren E. Abrey, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|